In its view, this 10 billion M&A fund is not only 10 billion yuan, but also a way for the government to encourage and guide M&A through the amplification of M&A funds. "In short, whether it is the M&A fund of the integrated circuit design industry or the M&A fund of biomedicine, the core purpose is to guide the orderly development of the industry and avoid the dependence on the IPO path, leading to excessive competition in the industry."However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
Since the second half of 2024, there have been frequent large-scale acquisitions in the A-share market, and the biomedical industry has accelerated its integration. For example, China Bio-Pharmaceutical intends to acquire about 55% equity of Haooubo by means of "agreement+offer", Qianhong Pharmaceutical plans to invest 390 million yuan for bankruptcy and reorganization of Fiona Fang Pharmaceutical, Pharmacists help to acquire a piece of medicine, Xinnuowei plans to acquire 100 grams of Shiyao, and Sichuan Shuangma announced the cross-border acquisition of Jianyuan Medicine ..."At present, the Yangtze River Delta has many excellent semiconductor enterprises and research institutions, while Shanghai has many top semiconductor design enterprises at home and abroad, such as Quanlun Electronics, Lanqi Technology, Fudan Microelectronics, Weir, Aojie Technology and Ziguang Zhanrui. The establishment of industrial mergers and acquisitions will help to integrate industry resources, promote industry agglomeration, and form a group of design companies with strength and key core technologies. " Yuan Shuai said.At the end of the year, Shanghai launched a big action in the field of mergers and acquisitions. Today, the General Office of the Shanghai Municipal People's Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027) (hereinafter referred to as the Action Plan).
Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.Bu Rixin believes that in the past few years, after the IPO tide of semiconductors, especially chip design companies, the IPO dividend period of chip design companies has basically ended. "Except for some large chip fields that have not been completely replaced, there are listed companies in other sub-fields, and these fields have already experienced serious involution at the level of low-end products. In the follow-up, if enterprises in these fields are encouraged to conduct IPOs, it is equivalent to encouraging disorderly competition in the industry. "
Strategy guide 12-13
Strategy guide
12-13